This inventor holds 1 USPTO granted patent. Top assignee: Yonsei University. Active years: 2019.
Company Filing History:
Years Active: 2019
Title: Innovations of Yu-Ra Choi in Cancer Drug Resistance
Introduction: Yu-Ra Choi is an accomplished inventor based in Gangwon, South Korea. He has made significant contributions to the field of cancer research, particularly in understanding drug resistance mechanisms. His innovative work focuses on the EI24 gene and its implications for improving the efficacy of anti-cancer drugs.
Latest Patents: Yu-Ra Choi holds a patent related to the use of the EI24 gene. The patent describes a novel application of EI24 in improving resistance to EGFR-TKI drugs by inhibiting IGF-1R signaling. This groundbreaking research indicates that the expression level of EI24 can be used to determine resistance to anti-cancer drugs. Furthermore, the patent outlines methods to inhibit, delay, or improve drug resistance through the use of EI24 or its activating agents. By regulating the EI24-mediated resistance pathway, the effectiveness of existing anti-cancer treatments can be enhanced.
Career Highlights: Yu-Ra Choi is affiliated with Yonsei University, where he conducts his research and contributes to the academic community. His work has garnered attention for its potential to transform cancer treatment strategies and improve patient outcomes.
Collaborations: Yu-Ra Choi collaborates with esteemed colleagues, including Byoung Chul Cho and Hye Ryun Kim. Their combined expertise enhances the research efforts and fosters innovation in the field of cancer therapy.
Conclusion: Yu-Ra Choi's contributions to cancer research through his patent on the EI24 gene exemplify the importance of innovation in overcoming drug resistance. His work not only advances scientific understanding but also holds promise for improving treatment options for cancer patients.